Parkinson’s disease clinical research in 7MM focuses on disease-modifying agents
Treatments targeting alpha-synuclein aggregation account for 26% of the 7MM pipeline of disease-modifying therapies for Parkinson's.
Comment & Opinion
Recent popularity of JAK inhibitors in atopic dermatitis
Tuberculosis screening efforts successful in vulnerable Canadian province
Vaping found to be a risk factor for female infertility
IDWeek 2024: the efficacy of SCY-247 in murine models of invasive fungal infections
Second Alzheimer’s drug rejected by NICE on the same day it is approved in the UK
IDWeek 2024: highlights on the detection and prevention of NTM outbreaks
Oral GLP-1 receptor agonist Rybelsus reduces risk of cardiovascular events in type 2 diabetes patients
